HK1197194A1 - Left ventricular diastolic function improving agent - Google Patents

Left ventricular diastolic function improving agent

Info

Publication number
HK1197194A1
HK1197194A1 HK14110827.2A HK14110827A HK1197194A1 HK 1197194 A1 HK1197194 A1 HK 1197194A1 HK 14110827 A HK14110827 A HK 14110827A HK 1197194 A1 HK1197194 A1 HK 1197194A1
Authority
HK
Hong Kong
Prior art keywords
left ventricular
improving agent
function improving
diastolic function
ventricular diastolic
Prior art date
Application number
HK14110827.2A
Other languages
English (en)
Chinese (zh)
Inventor
Toshiya Kanaji
Kazuhiro Fuchibe
Masaya Takahashi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197194A1 publication Critical patent/HK1197194A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HK14110827.2A 2011-08-02 2014-10-29 Left ventricular diastolic function improving agent HK1197194A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011169389 2011-08-02
PCT/JP2012/069609 WO2013018837A1 (ja) 2011-08-02 2012-08-01 左室拡張機能改善剤

Publications (1)

Publication Number Publication Date
HK1197194A1 true HK1197194A1 (en) 2015-01-09

Family

ID=47629356

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110827.2A HK1197194A1 (en) 2011-08-02 2014-10-29 Left ventricular diastolic function improving agent

Country Status (16)

Country Link
US (1) US9682065B2 (ru)
EP (1) EP2740475A4 (ru)
JP (1) JP6052175B2 (ru)
KR (1) KR20140056250A (ru)
CN (1) CN103717219B (ru)
AU (1) AU2012290987B2 (ru)
BR (1) BR112014002377A2 (ru)
CA (1) CA2842906A1 (ru)
HK (1) HK1197194A1 (ru)
IL (1) IL230686A0 (ru)
MX (1) MX2014000971A (ru)
RU (1) RU2627842C2 (ru)
SG (1) SG2014007603A (ru)
TW (1) TW201321003A (ru)
WO (1) WO2013018837A1 (ru)
ZA (1) ZA201401487B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3175852B1 (en) 2012-07-19 2019-03-06 Cayman Chemical Company, Incorporated Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
SG11201507470WA (en) 2013-03-15 2015-10-29 Cayman Chemical Co Inc Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
CA2910398A1 (en) 2013-07-19 2015-01-22 Cayman Chemical Company, Inc. Methods, systems, and compositions for promoting bone growth
JP6884420B2 (ja) * 2016-02-04 2021-06-09 クザップ リサーチ アンド デベロップメント エルエルシーCzap Research And Development, Llc 放出制御及び階層化シクロデキストリン包接体ビヒクル
US11479550B2 (en) 2017-05-22 2022-10-25 Ono Pharmaceutical Co., Ltd. EP4 antagonist
RU2762989C1 (ru) * 2020-09-28 2021-12-24 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ лечения собак, больных дилатационной кардиомиопатией, осложненной застойной сердечной недостаточностью

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS503362B1 (ru) 1970-06-10 1975-02-04
JPS5231404B1 (ru) 1971-04-28 1977-08-15
JPS57156460A (en) 1981-03-20 1982-09-27 Ono Pharmaceut Co Ltd Stabilized composition of prostaglandin and prostaglandin mimic compound, and its preparation
US5938890A (en) 1998-06-27 1999-08-17 Automatic Manufacturing Systems, Inc. Adhesive components peel and apply apparatus and method
AP2002002555A0 (en) 1999-12-22 2002-06-30 Pfizer Prod Inc EP4 Receptor selective agonists in the treatment of osteoporosis.
IL141120A0 (en) 2000-01-31 2002-02-10 Pfizer Prod Inc Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure
EP1312601A4 (en) 2000-08-22 2005-09-21 Ono Pharmaceutical Co CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
EP1409455B1 (en) * 2001-07-16 2006-01-04 F. Hoffmann-La Roche Ag Prostaglandin analogues-as ep4 receptor agonists
BR0211167A (pt) 2001-07-16 2004-08-10 Hoffmann La Roche Derivados de 2-pirrolidona como agonistas de prostanóides
WO2003009872A1 (en) * 2001-07-23 2003-02-06 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
JP4888775B2 (ja) 2004-08-10 2012-02-29 小野薬品工業株式会社 Ep4アゴニストを含有してなる下部尿路系疾患の予防および/または治療剤
US20080234337A1 (en) 2004-08-10 2008-09-25 Ono Pharmaceutical Co., Ltd. Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
JP2006321737A (ja) 2005-05-18 2006-11-30 Ono Pharmaceut Co Ltd Ep4アゴニストを含有する神経変性疾患の予防、治療および/または進展抑制剤

Also Published As

Publication number Publication date
AU2012290987A1 (en) 2014-02-20
CN103717219B (zh) 2017-02-15
SG2014007603A (en) 2014-03-28
JPWO2013018837A1 (ja) 2015-03-05
WO2013018837A1 (ja) 2013-02-07
US20140179606A1 (en) 2014-06-26
RU2014107904A (ru) 2015-09-10
CA2842906A1 (en) 2013-02-07
ZA201401487B (en) 2015-12-23
TW201321003A (zh) 2013-06-01
US9682065B2 (en) 2017-06-20
RU2627842C2 (ru) 2017-08-14
JP6052175B2 (ja) 2016-12-27
EP2740475A4 (en) 2015-02-25
CN103717219A (zh) 2014-04-09
MX2014000971A (es) 2014-02-27
BR112014002377A2 (pt) 2017-02-21
AU2012290987B2 (en) 2017-04-20
KR20140056250A (ko) 2014-05-09
EP2740475A1 (en) 2014-06-11
IL230686A0 (en) 2014-03-31
TWI562778B (ru) 2016-12-21
NZ620451A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
HK1199193A1 (en) Heart occlusion devices
HK1198893A1 (en) Heart occlusion devices
EP2890418A4 (en) VENTRICULAR CUFF
ZA201305801B (en) Heart valve
EP2647707A4 (en) THERAPEUTICS WITH CYTOTOXICITY INDICATION
PL2510864T3 (pl) Zmywarka do naczyń
ZA201403090B (en) Tropicalizing agent
GB201114212D0 (en) Therapeutic agents
PL2522268T3 (pl) Zmywarka do naczyń
HK1197194A1 (en) Left ventricular diastolic function improving agent
EP2928536A4 (en) TRANSCATHETER AORTIC VALVULE VENTRICULAR REPLACEMENT CATHETER (TAVR)
GB201119401D0 (en) Therapeutic agents
PL2609894T3 (pl) Zastawka serca
PL2543305T3 (pl) Zmywarka do naczyń
EP2777736A4 (en) SUCTION CATHETER
EP2796096A4 (en) MEDICAL PORT
PL2583613T3 (pl) Zmywarka do naczyń
IL232239A0 (en) Medical use
EP2767208A4 (en) DISHWASHER
GB2497286B (en) Catheter
PL2683284T3 (pl) Zmywarka do naczyń
EP2674157A4 (en) THERAPEUTIC AGENT FOR CONGESTIVE DIASTOLIC HEART INSUFFICIENCY
GB201114901D0 (en) Vascular treatments
EP2787050A4 (en) LECITHIN-Organogel formers
TWI562734B (en) Sense-improving agent